What Digital Infuzion does

Digital Infuzion, LLC is a privately held federal health informatics and IT services company founded in 1999 by Hemant Virkar, a former NIH technical lead, and headquartered in Rockville, Maryland. The company designs and operates custom informatics solutions for federal health and civilian agencies (notably NIH institutes including NIAID, NCI, NIA, and NIEHS; CMS; SEC; DTRA; and DHS), commercial pharmaceutical and biotech sponsors, non-profit research institutions, and standards bodies such as CDISC. Its core offerings combine two proprietary product platforms — GeneBrain®, an analytics and visualization platform built on patented self-optimizing machine learning (US8386401) and big-data visualization (US8812274) — and the N of 1 Health Research Platform, a cloud-based SaaS for patient registries, observational studies, and electronic patient-reported outcomes, with a specialized RegistryNXT! configuration for pharma rare-disease programs.

The underlying technology stack spans AI/ML (predictive analytics, NLP, generative AI via LLM fine-tuning and Retrieval Augmented AI on Microsoft Azure OpenAI, computer vision, and anomaly detection), cloud-native development on AWS and Azure using Agile DevSecOps, and integration with EMR/EHR systems, Medidata RAVE, CDISC standards, and wearables. Digital Infuzion also holds four ISO certifications (9001, 20000-1, 27001, 22301), CMMI Level 3 (Development and Services), and compliance postures covering HIPAA, GDPR, and 21 CFR Part 11.

The business model blends three revenue streams. The dominant stream is professional services delivered through federal IDIQ vehicles — CIO-SP3 (Small Business, 8(a), and Large Business via the INDUS-led HIITS CTA), the CMS SPARC contract (up to $25B shared ceiling, base period 2017-2022 with options to 2027), and GSA Schedule #47QTCA19D00FW through July 2029 — billed under T&M, FFP, and CPFF arrangements. A secondary stream is commercial healthcare/pharma IT consulting (Sanofi Genzyme, EMD Serono, Alexion, Agios, Alnylam, Sarepta, Ultragenyx and others). A third, still emerging stream is SaaS subscription revenue from the N of 1 platform, with pricing quote-based and annual billing. Go-to-market combines enterprise field sales via capture management and program leadership, channel partner teaming (INDUS, Armedia, Mentor-Protégé JVs Aspire, Digital Edge, Tera Fuzion), and federal procurement portal presence (GSA Advantage!, eBuy).

Name

Digital Infuzion

Legal name

Digital Infuzion, LLC

Website

https://digitalinfuzion.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Short description

Digital Infuzion is a privately held federal health informatics firm that builds AI-enabled clinical research and data analytics platforms (GeneBrain®, N of 1) for NIH, CMS, SEC, DTRA, DHS, pharmaceutical sponsors, and academic medical centers, delivered via CIO-SP3, SPARC, and GSA contract vehicles.

Ownership category

akta.pro rank

Product category

Clinical Research Informatics

NAICS

Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

akta.pro secondary industries

Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ), Data Management, Biostatistics & Statistical Programming FSP (HLAGAOAB), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Clinical informatics services
• Biomedical data analytics
• Patient registry software
• Health IT consulting
• Federal health IT

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Federal Government IT Services: Professional IT services delivered to federal agencies through multiple IDIQ contract vehicles including CIO-SP3 (Small Business, 8(a), Large Business), SPARC (CMS), and GSA Schedule. Services include software engineering, clinical informatics, bioinformatics, health IT, cloud services, data science, cybersecurity, and enterprise application services. Revenue generated through time-and-materials (T&M), firm-fixed-price (FFP), cost-plus-fixed-fee (CPFF), and various other contract types.
2. Commercial Healthcare IT Services: IT consulting and implementation services for commercial healthcare organizations, pharmaceutical companies, biotech firms, and non-profit health research institutions. Services include digital transformation, clinical research systems, data analytics, and regulatory compliance solutions.
3. N of 1 Health Research Platform (SaaS): The N of 1 Platform is offered as a cloud-based SaaS disease management solution providing electronic patient reported outcomes, analytics, EDC integration, and patient registry capabilities. Customers include pharmaceutical companies, biotech companies, patient advocacy/non-profit groups, and academic organizations implementing Patient Registries and Observational Studies in the rare disease domain.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Core offering

Digital Infuzion delivers clinical informatics services and proprietary software platforms to federal health agencies, defense agencies, pharmaceutical sponsors, and non-profit/academic medical centers. Its core commercial products are the GeneBrain® data analytics platform (with patented self-optimizing machine learning and 3D visualization) and the N of 1 Health Research Platform (a cloud-based SaaS for patient registries, ePRO, and observational studies). The majority of revenue is generated through federal IT services delivered under CIO-SP3, SPARC, and GSA Schedule contract vehicles using T&M, FFP, and CPFF task orders.

Product overview

Digital Infuzion offers a portfolio of proprietary products centered on two core platforms: GeneBrain® and the N of 1 Health Research Platform. GeneBrain® is a data analytics solution that applies patented self-optimizing machine learning algorithms and 3D visualization technology to complex biological and clinical data, enabling researchers to identify predictive biomarkers and discover patterns across large datasets. The N of 1 Health Research Platform is a cloud-based SaaS disease management and patient registry solution that integrates electronic patient-reported outcomes (ePRO), clinical data capture (EDC), and EMR interoperability to support observational research, rare disease registries, and patient-centric outcomes studies. The company also holds two foundational patents — Machine Learning Methods (US8386401) for automated predictive analytics and Visualizing Big Data (US8812274) for 3D data visualization — which underpin capabilities across both platforms. RegistryNXT! is a specialized configuration of the N of 1 platform built for pharmaceutical rare disease registries. Together, these products form an integrated ecosystem for translational research, from molecular data analysis to patient-level clinical outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• GeneBrain®: A data analytics solution that allows researchers and clinicians to gain at-a-glance insights into complex biological data using 3D visualizations and patented self-optimizing learning machines.
• N of 1 Health Research Platform

Products and services

• GeneBrain® A proprietary data analytics solution that models large volumes of complex biological data for monitoring, classification of samples, repository querying, biomarker identification, and hypothesis refinement and validation. Uses patented self-optimizing learning machines and 3D visualizations that make biological discoveries intuitive for biomedical researchers, clinical scientists, and pharmaceutical sponsors.
• N of 1 Health Research Platform A real-time, patient-centric, web-based, mobile-friendly SaaS disease management and analytics platform for observational studies and patient registries. Features include electronic patient reported outcomes (ePRO), EDC and EMR integration, patient registry capabilities, GDPR/GCP/21 CFR Part 11/HIPAA compliance, and integration with wearables and biometric devices. Customers include pharmaceutical companies, biotech firms, patient advocacy groups, and academic organizations in the rare disease domain.
• RegistryNXT! Platform A specialized implementation of the N of 1 Health Research Platform for managing rare disease registries, including for Sanofi Genzyme. Features CDISC-compliant data interchange, integration with Medidata's RAVE, role-based disease management, and regulatory reporting capabilities for pharmaceutical sponsors.

Quantifiable outcome

• N of 1 Platform achieves 94%+ predictive accuracy in muscle tissue analysis using GeneBrain®
• +4 more outcomes

Named customers24 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability13 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core, minor and strategic.

• INDUS CorporationcoreStrategic or Co-development Partner · 1 January 2012INDUS Corporation is the lead and contract holder for the CIO-SP3 Large Business GWAC through the HIITS CTA. Digital Infuzion is a strategic partner in this Contractor Team Arrangement fulfilling NITAAC's vision for CIO-SP3 GWAC serving NIH and all federal agencies.
• Armedia, LLCcoreStrategic or Co-development Partner · 1 January 2012Armedia participates as CTA partner in both CIO-SP3 Large Business (HIITS CTA with INDUS) and CIO-SP3 8(a) Business (CIO Source CTA with Digital Infuzion). Armedia provides technology integration and data management capabilities for federal health IT contracts.
• Aspire InformaticsminorOthers8(a) Joint Venture partner in Digital Infuzion's Mentor-Protégé Program. Aspire Informatics participates as a protégé organization benefiting from Digital Infuzion's domain expertise, business reputation, and resources.
• Digital EdgeminorOthersWOSB (Women-Owned Small Business) Joint Venture partner in Digital Infuzion's Mentor-Protégé Program. Digital Edge participates as a protégé gaining access to Digital Infuzion's corporate capabilities while expanding market reach.
• Tera FuzionminorOthersSDVOSB (Service-Disabled Veteran-Owned Small Business) Joint Venture partner in Digital Infuzion's Mentor-Protégé Program. Tera Fuzion collaborates with Digital Infuzion on federal contracting opportunities.
• Carson AssociatesminorStrategic or Co-development PartnerCarson Associates participates as CTA partner in Digital Infuzion's CIO Source™ arrangement for CIO-SP3 8(a) Business GWAC, providing specialized technical capabilities for federal contracting engagements.
• Partner EcosystemcoreChannel Partner/ Reseller/ DistributorDigital Infuzion maintains a diverse partner ecosystem of small businesses to large organizations with well-known brands to address complex Cloud services, cybersecurity, and data analytics challenges. Partners are assembled per customer requirement to deliver modern transformative solutions.
• CDISC (Clinical Data Interchange Standards Consortium)strategicStrategic or Co-development PartnerDigital Infuzion serves on the CDISC Industry Advisory Board. The company helps standards organizations do their work by building web-based collaboration environments and providing services to enhance CDISC's business and data management activities. CDISC membership supports the company's healthcare data standardization mission.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• IQVIA: Global clinical research services and technology vendor (formerly QuintilesIMS) competing head-to-head with DIFZ's N of 1 platform in rare disease registries, EDC, ePRO, and RWE/observational studies. Much larger commercial pharma focus and global footprint, but a frequent competitor and partner on registry initiatives.
• Booz Allen Hamilton: Large public consulting firm with a major federal health IT practice (NIH, HHS, CMS, FDA) including health analytics, biosurveillance, and clinical research informatics. Competes with DIFZ on CIO-SP3 task orders and similar large federal health IT procurements but at vastly larger scale and broader capability footprint.
• ICF International: Public consulting firm providing digital transformation, health analytics, and IT modernization to HHS, CMS, NIH, and CDC. Competes on overlapping federal health IT/RWE/biostatistics task orders with DIFZ but at significantly larger scale and broader commercial/government portfolio.
• Leidos: Large public systems integrator with a substantial federal health and life sciences practice (NIH, CMS, FDA, DoD health) offering informatics, clinical research support, and biosurveillance. Competes with DIFZ on CIO-SP3 and SPARC task orders at a vastly larger scale.

Direct peers

• Emmes Group: Private clinical research and biostatistics services organization serving NIH institutes (NIAID, NCI, NEI), FDA, and biopharma with patient registries, EDC, and data coordination. Highly comparable: similar size, biomedical research focus, founder-friendly federal culture, and DIFZ's CHRO Jennifer Fairfax previously served as CHRO at Emmes.
• NORC at the University of Chicago: Non-profit research organization with strong federal health research IT practice including data coordination centers, biostatistics, and survey research for NIH, CMS, and HHS. Closely comparable by mission, federal health research focus, and clinical research informatics service mix (DIFZ is even mentioned as a collaborator context).
• DLH Holdings Corp: Public federal health and science IT services company of comparable size, providing digital transformation, clinical research support, and program management to NIH, CDC, DoD, and CMS. Directly comparable on contract vehicles, federal health focus, and biomedical informatics delivery model—DIFZ's CGO Davyd Chung previously served as VP at DLH.
• Mathematica Policy Research: Non-profit research organization with deep federal health research and data analytics practice serving HHS, CMS, NIH, and patient advocacy groups. Comparable on research IT, observational studies, and survey/data coordination for federal health; overlapping on data standards work.
• RTI International: Non-profit research institute with a large federal health research IT and biostatistics practice serving NIH, FDA, and global health agencies. Comparable in clinical research informatics, patient registries, and federal contracting model—DIFZ is a vendor to RTI for the PopGen typhoid vaccine study using GeneBrain®.

Emerging players

• Quartz Bio (or Crucial Data Solutions / Clinical Ink): Specialty ePRO/EDC and clinical trial technology providers focused on rare disease registries and patient-centric studies. Comparable to N of 1 in product category, customer segment (biotech/non-profit disease foundations), and SaaS delivery model—representing real potential share competition in DIFZ's rare disease sweet spot.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/digitalinfuzion
• LinkedInlinkedin.com/company/48862

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Digital Infuzion